(1 g/day, orally) for a median duration of 7 months (range, 6-11 months) initially, whereas the remaining patients (9 Stage B patients and 7 Stage C patients) received 1 Department of Medical Oncology, Ibn-i Sina combination chemotherapy (cyclophosphamide, vincristine, procarbazine, and Hospital, Ankara University School of Medicine, prednisolone [COPP regimen]) followed by tetracycline at a dose of 1 g/day for 6 Sihhiye-Ankara, Turkey.more months in patients with complete response (CR) after the COPP regimen. 2 Department of Gastroenterology, Ibn-i Sina RESULTS. The median follow-up was 68 months (range, 38-89 months). As first-Hospital, Ankara University School of Medicine, line therapy in Stage A patients, tetracycline yielded a 71% CR and 43% disease Sihhiye-Ankara, Turkey.free survival (DFS) rate. Eleven of 16 patients (69%) with Stage B or C disease who 3 Department of Third Internal Medicine, SSK received the COPP regimen achieved CR and only 2 patients had a recurrence Hospital, Diskapi-Ankara, Turkey.(DFS rate of 56%). The 5-year overall survival (OAS) rate for the entire group was 70%, and the 5-year DFS rate for patients with CR was 75%. However, the median

Prurigo pigmentosa is a relatively new clinical entity, and we believe that a more widespread knowledge of this disease will lessen its misdiagnosis. We find it noteworthy to point out that there may be a predisposition to prurigo pigmentosa amongst the Turkish and Sicilian populations.

The aim of this study was to investigate the relationship between prostate specific antigen density and prostate volume with microvessel density in patients with benign prostatic hyperplasia and advanced prostatic carcinoma. Sixty-eight patients with benign prostatic hyperplasia and 11 patients with advanced prostatic carcinoma participated in the study. The paraffin blocks of all patients were stained with CD34 by the standard immunohistochemical technique and microvessel density, prostate specific antigen density and prostatic volume were determined. In patients with benign prostatic hyperplasia the mean microvessel density, mean prostate specific antigen density and mean prostatic volume were 74+/-89+/-22.73, 0.12+/-0.10 and 59.97+/-27.0 ml, respectively. There was no correlation between prostate specific antigen density and mean prostatic volume or microvessel density (r = 0.079 and -0.095, respectively). In patients with advanced prostatic carcinoma the mean microvessel density, mean prostate specific antigen density and mean prostatic volume were 147.90+/-47.55, 0.63+/-0.41 and 54.00+/-22.42 ml, respectively. In this group, while there was a good correlation between prostate specific antigen density and microvessel density (r = 0.785), no significant correlation was found between prostatic volume and microvessel density (r = -0.07). There was significant statistical difference in patients with advanced prostatic carcinoma compared to patients with benign prostatic hyperplasia in terms of mean microvessel density (p<0.0001). The findings that there was no correlation between prostatic volume and MVD either in benign prostatic hyperplasia or in prostatic carcinoma suggest that microvessel development is not correlated with prostatic volume but may be correlated with morphology.

No abstract

No abstract